OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Paik on the Full FDA Approval of Tepotinib for mNSCLC Harboring MET Exon 14 Skipping Alterations

March 30th 2024

Paul K. Paik, MD, discusses the FDA approval of tepotinib for metastatic non–small cell lung cancer harboring MET exon 14 skipping alterations.

Dr Sotomayor on the Integration of BTK Inhibitors into the CLL Treatment Arsenal

March 29th 2024

Eduardo Sotomayor, MD, discusses the current arsenal of BTK inhibitors in chronic lymphocytic leukemia.

Dr Knight on Diagnosing and Managing Brain-Metastatic Prostate Adenocarcinoma

March 29th 2024

James Knight, MD, discusses a case study of a patient with brain-metastatic prostate adenocarcinoma.

Dr Sabari on the FDA Approval of Frontline Amivantamab Plus Chemo in EGFR Exon 20 Insertion+ NSCLC

March 29th 2024

Joshua K. Sabari, MD, discusses the FDA approval of frontline amivantamab plus chemotherapy for NSCLC harboring EGFR exon 20 insertion mutations.

Dr Galsky on the FDA Approval of Nivolumab Plus Chemotherapy in Urothelial Carcinoma

March 29th 2024

Matthew Galsky, MD, discusses the significance of the FDA approval of frontline nivolumab plus chemotherapy patients with metastatic urothelial carcinoma.

Dr Li on the Utility of ADG126 Plus Pembrolizumab in MSS CRC

March 29th 2024

Daneng Li, MD, discusses the implications of a study evaluating ADG126 in combination with pembrolizumab in patients with MSS colorectal cancer.

Dr Goy on Real-World Outcomes With CAR T-Cell Therapy in MCL

March 29th 2024

Andre Goy, MD, discusses the implementation of CAR T-cell therapy in patients with relapsed/refractory mantle cell lymphoma.

Dr Dotan on Treating Geriatric Patients With Gastroesophageal Cancer

March 29th 2024

Efrat Dotan, MD, discusses a retrospective study aiming to understand the needs of geriatric patients with gastroesophageal cancer.

Dr Baz on AE Management Discussions in Multiple Myeloma

March 29th 2024

Rachid Baz, MD, discusses the importance of educating patients about potential adverse effects associated with multiple myeloma treatments.

Dr Bilusic on the Non-ccRCC Treatment Armamentarium

March 29th 2024

Marijo Bilusic, MD, PhD, discusses combination regimens under investigation for patients with non–clear cell renal cell carcinoma.

Dr Antonarakis on Community Enrollment in the ECLIPSE Trial in Prostate Cancer

March 29th 2024

Emmanuel Antonarakis, MD, discusses community enrollment in the ECLIPSE trial in prostate cancer.

Drs Jha and Antonarakis on Collaboration Between Community and Academic Oncologists

March 29th 2024

Gautam Jha, MD, and Emmanuel Antonarakis, MD, on the advantages of collaborative efforts between community and academic oncologists.

Dr Parrondo on the Use of Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma

March 28th 2024

Ricardo D. Parrondo, MD, discusses the CARTITUDE-4 trial of cilta-cel in lenalidomide-refractory multiple myeloma.

Dr Sahin on the Utility of the Northstar Response Assay in GI Cancer

March 28th 2024

Ilyas Sahin, MD, discusses the potential utility of Northstar Response assay in patients with advanced gastrointestinal cancer.

Dr Singh on Treating Lung Cancer CNS Metastasis Management Strategies

March 28th 2024

Raj Singh, MD, discusses treating patients with lung cancer with CNS metastases.

Dr Merchán on the Role of Immunotherapy and TKI Combinations in RCC

March 28th 2024

Jaime R. Merchán, MD, discusses the current roles for immunotherapy and TKIs in patients with renal cell carcinoma.

Dr Kenderian on Moving Liso-Cel to the First Line of CLL Treatment

March 28th 2024

Saad J. Kenderian, MB, CHB, discusses ongoing research taking place to potentially move liso-cel into earlier lines of therapy for patients with CLL.

Dr Phillips on Ongoing Research in High-Risk MCL

March 28th 2024

Tycel Phillips, MD, MPH, discusses ongoing trials for patients with high-risk mantle cell lymphoma.

Dr Mehta on Radiation Oncology Innovations in Prostate Cancer

March 28th 2024

Minesh Mehta, MD, discusses recent advancements in radiation oncology approaches for patients with prostate cancer.

Dr Kummar on the Evaluation of Rezatapopt in Advanced Solid Tumors

March 27th 2024

Shivaani Kummar, MD, FACP, discusses the evaluation of rezatapopt in patients with advanced solid tumors.